Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether calcineurin phosphatase in the T-lymphocytes is up-regulated after long-term treatment with tacrolimus, a calcineurin inhibitor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

NCT00282568

Kidney Transplantation

COMPLETED PHASE2

Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection

NCT00133172

Kidney Transplantation

TERMINATED PHASE4

The Differential Effects of 3 Different Immunosuppressive

NCT00729248

Immunosuppression Kidney Transplantation

COMPLETED

Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.

NCT02278952

Transplantation, Lung

COMPLETED

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255

Kidney Transplant Delayed Graft Function

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

The immunosuppressive effect of both tacrolimus and cyclosporine is believed to be through inhibition of the enzyme calcineurin phosphatase (CaN) in T-lymphocytes. We have demonstrated, that tacrolimus decreases CaN activity in patients early after renal transplantation. In stable renal transplant patients treated this inhibition was hardly seen in patients treated with tacrolimus, while it was clearly demonstrated in patients treated cyclosporine. One explanation to this finding could be, that calcineurin phosphatase is up-regulated by long-term treatment with tacrolimus. The findings seem to imply, that tacrolimus has mechanisms of immunosuppression apart from inhibiting CaN. This could have implications for side-effects due to CaN inhibition. Among side-effects thought to be due to CaN inhibition is nephrotoxicity. The results may therefore be and indication of tacrolimus being less nephrotoxic compared to cyclosporine in long-term stable renal transplant patients.

Purpose:

The aim of the project is find out if long-term treatment with tacrolimus results in up-regulation of CaN in lymphocytes.

Study plan:

The general plan of the investigation is to compare CaN in lymphocytes in two groups of renal transplant patients treated with tacrolimus. One group just prior and just after transplantation compared to a group of stable renal transplanted patients a long time after transplantation. CaN is determined as enzyme activity, amount of protein, and by gen-activation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early kidney-transplant recipients

Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.

No interventions assigned to this group

stable kidney transplant recipients

Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 1 (early kidney-transplant recipients)

* Age over 18 years
* 20 consecutively kidney-transplant recipients at Department of Nephrology, Aarhus University Hospital, Skejby, Denmark
* receiving tacrolimus as part of their immunosuppressive treatment
* receipt of graft from either deceased or living-related donor
* written consent to participate

Group 2 (stable kidney-transplant recipients)

* Age over 18 years
* Stable renal allograft function defined as S-creatinine \<200 µmol/l
* variation in S-creatinine \<20% for 6 months prior to inclusion
* kidney transplantation more than 2 years before inclusion
* receipt of graft from either deceased or living-related donor
* written consent to participate

Exclusion Criteria

Group 1 (early kidney-transplant recipients)

* patients suspected of non-compliance
* patients receiving medications known to interact with tacrolimus pharmacokinetics
* patients who on day 8 after transplantation have not reached a trough level for blood tacrolimus concentration above 8 µg/l.

Group 2 (stable kidney-transplant recipients)

* patients suspected of non-compliance
* patients receiving medications known to interact with tacrolimus pharmacokinetics

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes